Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
In a controlled clinical inpatient trial (n = 93) comparing the efficacy and safety of brofaromine versus tranylcypromine for 6 weeks in treatment-resistant major depressed patients, the two drugs were found to be of comparable afficacy and tolerability. The response rate (a 50% reduction) on the Hamilton Scale for Depression (HAMD) in both groups was about 73%. The most common side effects in the brofaromine group were sleep disorders, hypotension, tremor and dryness of mouth; and in the tranylcypromine group sleep disorders, fatigue, hypotension, tremor and vertigo. Methodological and practical clinical implications of the results are discussed.
Volz
H P
HP
Department of Psychiatry, University of Bonn, Germany.
Faltus
F
F
Magyar
I
I
Möller
H J
HJ
D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010555:Personality Inventory; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D014191:Tranylcypromine / Q000009:adverse effects / Q000627:therapeutic use*
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; D014191:Tranylcypromine; C038213:brofaromine